【24h】

Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia.

机译:金黄色葡萄球菌菌血症患者的长期结果和护理质量。

获取原文
获取原文并翻译 | 示例
       

摘要

To assess the long-term outcome and influence of clinical management of patients with Staphylococcus aureus bacteremia (SAB), 229 patients with blood cultures positive for Staphylococcus aureus between January 1997 and December 2000 were retrospectively identified and followed up. Risk factors, source of infection, treatment, clinical course, and outcome were recorded by chart review. For the assessment of 1-year survival, a questionnaire was sent to family doctors and government registration offices. Time of initial antibiotic therapy, duration of antibiotic treatment and performance of echocardiography were regarded as indicators of the quality of the clinical management of SAB. Among the 229 patients studied, 218 were evaluable for 1-year survival. Crude mortality after 1 year was 37.6% year. Within 30 days 43 (19.7%) patients had died, and 39 (17.9%) additional patients died thereafter. Using multivariate analysis, the following variables were associated with death: malignant disease (odds ratio [OR] 4.8; 95% confidence interval [CI], 2.6-8.9), pneumonia (OR, 3.6; 95%CI, 1.2-10.2), age >60 years (OR, 2.6; 95%CI, 1.5-4.5), and known source of infection (OR, 2.3; 95%CI, 1.3-4.1). Among 160 patients with a completely assessable treatment course 73 (46%) had received antibiotics for at least 14 days. A delay of antibiotic treatment of 1 day or more after microbiological diagnosis was observed in 28.3% of patients (i.e., 60 of 212 patients who received at least 1 dose of antibiotics). Echocardiography was performed in 101 (44.1%) cases. Overall, the findings indicate that standard guidelines for the management of SAB are followed only in part in clinical practice. In order to reduce the considerable mortality associated with SAB and to improve short- and long-term outcome, efforts should be made to increase adherence to recommendations.
机译:为了评估金黄色葡萄球菌菌血症(SAB)患者的长期结果和临床管理影响,回顾性鉴定并随访了1997年1月至2000年12月间229例血液培养阳性金黄色葡萄球菌患者。通过图表审查记录危险因素,感染源,治疗,临床过程和结果。为了评估1年生存期,向家庭医生和政府注册办公室发送了问卷。初始抗生素治疗的时间,抗生素治疗的持续时间以及超声心动图的表现被认为是SAB临床管理质量的指标。在研究的229位患者中,有218位可评估1年生存率。 1年后的粗死亡率为37.6%年。在30天内,有43名(19.7%)患者死亡,此后又有39名(17.9%)患者死亡。使用多变量分析,以下变量与死亡相关:恶性疾病(赔率[OR] 4.8; 95%置信区间[CI],2.6-8.9),肺炎(OR,3.6; 95%CI,1.2-10.2),年龄> 60岁(OR,2.6; 95%CI,1.5-4.5),以及已知的感染源(OR,2.3; 95%CI,1.3-4.1)。在160例治疗过程完全可评估的患者中,有73例(46%)接受了至少14天的抗生素治疗。在微生物学诊断后,有28.3%的患者(即212例接受至少1剂抗生素的患者中有60例)观察到抗生素治疗延迟了1天或更长时间。 101例(44.1%)患者进行了超声心动图检查。总体而言,研究结果表明,仅在临床实践中部分遵循SAB管理的标准指南。为了降低与SAB相关的可观死亡率,并改善短期和长期结果,应努力提高对建议的依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号